Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jun;17(3):451-456.
doi: 10.1007/s12328-024-01931-0. Epub 2024 Feb 23.

Conversion therapy with pembrolizumab for a peritoneal metastasis of rectal cancer causing hydronephrosis in a patient with Lynch syndrome

Akio Matsumoto  1 , Yoshifumi Shimada  2   3 , Mae Nakano  1   4 , Hikaru Ozeki  1 , Daisuke Yamai  1 , Masaki Murata  4   5 , Fumio Ishizaki  4   5 , Hiromi Nyuzuki  6 , Takeshi Ikeuchi  6 , Toshifumi Wakai  1   4
Affiliations
Case Reports

Conversion therapy with pembrolizumab for a peritoneal metastasis of rectal cancer causing hydronephrosis in a patient with Lynch syndrome

Akio Matsumoto et al. Clin J Gastroenterol. 2024 Jun.

Abstract

A 44-year-old woman with Lynch syndrome was referred to our hospital for treatment of recurrence of microsatellite instability-high rectal cancer. [18F]Fluorodeoxyglucose (18FDG)-positron emission tomography revealed a peritoneal metastasis with invasion to the small intestine and left ureter. The peritoneal metastasis was diagnosed initially as unresectable because of extensive invasion to the left ureter requiring nephrectomy. Hence, first-line treatment with pembrolizumab was started. After the first course of pembrolizumab, she developed hydronephrosis and a resulting urinary tract infection (UTI). A percutaneous nephrostomy was performed to control the UTI. After six courses of pembrolizumab, 18FDG-positron emission tomography showed that the peritoneal metastasis was smaller with significantly reduced 18FDG uptake, and it was then diagnosed as resectable without nephrectomy. She underwent R0 resection of the peritoneal metastasis with partial resection of the small intestine. Intraoperatively, the peritoneal metastasis showed no invasion of the left ureter, allowing its preservation. The percutaneous nephrostomy was removed postoperatively, and she has not developed any subsequent UTIs. Histopathologically, the tumor showed a pathological complete response to pembrolizumab. To the best of our knowledge, this is the first case of conversion therapy with pembrolizumab for peritoneal metastasis with hydronephrosis.

Keywords: Conversion therapy; Hydronephrosis; Pembrolizumab; Peritoneal metastasis; Rectal cancer.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Tomasello G, Petrelli F, Ghidini M, et al. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA Oncol. 2017;3: e170278. - DOI - PubMed - PMC
    1. Maeda Y, Shinohara T, Nagatsu A, et al. Long-term outcomes of conversion hepatectomy for initially unresectable colorectal liver metastases. Ann Surg Oncol. 2016;23:242–8. - DOI
    1. Delaunoit T, Alberts SR, Sargent DJ, et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from intergroup N9741. Ann Oncol. 2005;16:425–9. - DOI - PubMed
    1. Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17:1709–19. - DOI - PubMed
    1. Aiken T, Hu CY, Uppal A, et al. Peritoneal recurrence after resection for stage I–III colorectal cancer: a population analysis. J Surg Oncol. 2023;127:678–87. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources